Home

Jeffrey Stein

CIK 1478831 · President & CEO · last filed 2026-06-18

Jeffrey Stein is a President & CEO who has filed 64 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for IDYA, was dated Jun 18, 2026. Across all open-market trades the lifetime net is +$3.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.30M

Companies

4

Total Filings

64

Lifetime Open-Market Net

$3.92M

Filer Profile

Reported Address
6310 NANCY RIDGE DRIVE, SUITE 101
SAN DIEGO, CA 92121
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
IDYA Director 57,644 $39.86 $2.30M $1.65M 9 2026-06-18
Cidara Therapeutics, Inc. (CDTX) Delisted President & CEO 10,072 $221.38 $2.23M $2.31M 36 2026-01-07
Paratek Pharmaceuticals, Inc. (PRTK) Delisted Director 0 $2.23 $0 -$37.4K 12 2023-09-21
Trius Therapeutics Inc (TSRX) Delisted President and CEO 210,457 — — $0 6 2013-03-11

Recent Filings

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-18 IDYA Grant (A) — $0 EDGAR
2026-03-02 IDYA Buy (P) +50,000 $1.65M EDGAR
2026-01-07 Cidara Therapeutics, Inc. (CDTX) Delisted Mixed −1,864 $0 EDGAR
2026-01-07 Cidara Therapeutics, Inc. (CDTX) Delisted Disp (D) −75,640 -$16.75M EDGAR
2025-12-29 Cidara Therapeutics, Inc. (CDTX) Delisted Gift (G) −5,425 $0 EDGAR
2025-12-12 Cidara Therapeutics, Inc. (CDTX) Delisted Tax (F) −2,285 -$501.8K EDGAR
2025-06-26 IDYA Grant (A) — $0 EDGAR
2025-04-02 Cidara Therapeutics, Inc. (CDTX) Delisted Grant (A) — $0 EDGAR
2024-10-02 Cidara Therapeutics, Inc. (CDTX) Delisted Grant (A) — $0 EDGAR
2024-06-11 Cidara Therapeutics, Inc. (CDTX) Delisted Buy (P) +8,000 $105.7K EDGAR
Showing 1–10 of 64
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.